Shilpa Medicare subsidiary commissions ADC GMP facility in Dharwad

Shilpa Biologicals Pvt Ltd, a material subsidiary of Shilpa Medicare , has commissioned a state-of-the-art Antibody-Drug Conjugate (ADC) GMP Manufacturing Facility in Dharwad. The facility is designed to meet global regulatory approval standards including US FDA and EMA requirements. It is fully operational, with GMP qualification protocols now actively underway, placing the company on a path to commercial readiness.

Strategic Expansion and Capabilities

The commissioning marks a significant evolution of Shilpa Medicare's over 25 years of expertise in highly potent compound manufacturing. The company has established a robust High Potency API (HPAPI) platform, which demands exacting standards of containment and safety engineering. With this new facility, Shilpa Medicare becomes one of the very few companies in India to offer fully integrated, end-to-end ADC Drug Substance development and manufacturing.

Integrated Service Offering

The new facility enables the company to provide a comprehensive range of services, encompassing payload synthesis, linker development and manufacturing, monoclonal antibody production, ADC conjugation, and purification of GMP-scale Drug Substance. This positions Shilpa Medicare as a cost-competitive Contract Development and Manufacturing Organization (CDMO) partner for global pharmaceutical and biotech companies.

Feature	Description
Facility Type	Antibody-Drug Conjugate (ADC) GMP Manufacturing Facility
Status	Fully Operational; GMP qualification protocols underway
Regulatory Standards	US FDA, EMA, and other major health authority requirements
Key Capabilities	Payload synthesis, linker development, mAb production, conjugation, purification

Management Commentary

Sridevi Khambhampaty, CEO of Shilpa Biologicals Pvt Ltd, highlighted that the manufacturing of highly potent compounds has been a core pillar of the company's identity. She stated that the ADC Drug Substance facility adds a sophisticated dimension to the group's capabilities, offering global partners an integrated facility built on high potency manufacturing excellence.

Vishnukant Bhutada, Managing Director of Shilpa Medicare Ltd, noted that India now possesses the infrastructure to be a trusted partner in global ADC Drug Substance manufacturing. He emphasized that the company's 25-year legacy in high potency manufacturing provides a distinct advantage, allowing it to provide a comprehensive one-stop solution to oncology innovators. The commissioning reinforces Shilpa Medicare's commitment to high-value biologics and innovation-driven GMP manufacturing, representing a decisive step in its strategy to become a globally relevant CDMO partner for advanced oncology ADC Drug Substance manufacturing.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.39%	-0.14%	+16.59%	+79.30%	-33.85%	+107.70%

Shilpa Medicare Limited shareholders have approved a special resolution to shift the company's registered office from one state to another and alter the situation clause of the Memorandum of Association. The resolution received 99.99% votes in favour, with 10,73,21,472 shares voting yes and 1,195 shares voting no. The postal ballot results were declared on June 23, 2026, following a voting process conducted via remote e-voting.

The postal ballot notice was issued on May 22, 2026, and the e-voting period commenced on May 24, 2026, at 09:00 a.m. IST, concluding on June 22, 2026, at 05:00 p.m. IST. The votes were unblocked and downloaded on June 23, 2026, at 11:12 a.m. IST from the portal of KFin Technologies Limited, the authorized agency engaged for the remote e-voting facility.

Scrutinizer's Report

The report was submitted by Santhosh Kumar Gunemoni, Partner, VCAN & Associates, Practicing Company Secretaries, who was appointed as the scrutinizer for the postal ballot process. The scrutinizer confirmed that the resolution was passed with the requisite majority based on the votes cast as "Assent" or "Dissent" / "For" or "Against".

The shareholders of the company holding shares as of the cut-off date, May 15, 2026, were entitled to vote on the resolution. The management of the company was responsible for ensuring compliance with the Companies Act, 2013, and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Voting Results

The detailed voting results are as follows:

Resolution Number	Resolution Type	Description	Mode of Voting	Total Number of Votes Cast	Votes in favour of the resolution		Votes against the resolution
					Yes	%	No	%
1	Special Resolution	Shifting Of Registered Office of The Company from One State to Another State and To Alter the Situation Clause of The Memorandum of Association.	Remote E- Voting	10,73,22,667	10,73,21,472	99.99	1195	0.01

The company has requested the stock exchanges to take the above information on their records. The corporate relationship departments of BSE Limited and National Stock Exchange of India Ltd. were informed of the declaration of the postal ballot results.